Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Shire website breaches UK pharma code

But healthcare professional section of vpriv.co.uk cleared of breaking marketing rules

Shire Vpriv UK website

A website produced by Shire to provide UK patients and healthcare professionals with information on its Gaucher disease drug Vpriv has fallen foul of pharma industry rules.

The site, www.vpriv.co.uk, was responsible for four breaches of the Association of the British Pharmaceutical Industry's (ABPI) Code of Practice after Shire's rival Genzyme complained about it.

But a complaint that Shire had not followed digital marketing rules, in the process making information on prescription-only medicines available online to the general public, was thrown out.

One of the ABPI Code's lessor known rules allows UK pharma companies to run 'brandname.com' websites to provide different types of information to patients and healthcare professionals.

In the US such sites are synonymous with direct-to-consumer (DTC) advertising, something strictly prohibited in the UK and the rest of Europe, so UK versions of these sites need clearly differentiated sections for their two different audiences.

In this case Code regulator the Prescription Medicines Code of Practice Authority (PMCPA) said Shire's Vpriv website achieved this and consequently did not breach clause 24.1 of the Code.

In its report on the complaint, published in the February 2012 Code of Practice Review, the PMCPA noted Genzyme “strongly believed that patients should have access to reliable, balanced and clear information about their disease and treatment”.

But, the PMCPA said, the company had argued Shire's website “allowed easy access to all promotional claims, including those which Genzyme considered to be disparaging, inaccurate and unsubstantiated”.

Shire said it was “particularly dismayed” by this last part of the complaint and considered Genzyme to be “time wasting”, according to the PMCPA report.
Genzyme markets its own Gaucher disease drug Cerezyme which, like Vpriv, is an enzyme replacement therapy.

The rule breaches, which came under clauses 7.2 and 7.3 of the Code, concerned claims made on the site about Vpriv's efficacy, manufacturing process and components.

23rd April 2012

From: Marketing

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics